CD4 and cholangiocarcinoma: However, since CD4+ T cells were also present as a considerable fraction (∼40%) in the post-REP T cells and adoptive transfer of CD4+ T cells is reported to be capable of managing various cancers including cholangiocarcinoma and melanoma successfully [13, 33], we cannot exclude a significant contribution by the CD4+ T cells to the anti-tumor immune response.